Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) EBT (2016 - 2025)

Historic EBT for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to -$20.4 million.

  • Abeona Therapeutics' EBT rose 3274.31% to -$20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.5 million, marking a year-over-year increase of 22729.15%. This contributed to the annual value of -$68.4 million for FY2024, which is 4387.95% down from last year.
  • As of Q3 2025, Abeona Therapeutics' EBT stood at -$20.4 million, which was up 3274.31% from $124.3 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' EBT registered a high of $124.3 million during Q2 2025, and its lowest value of -$46.7 million during Q4 2021.
  • Its 5-year average for EBT is -$8.7 million, with a median of -$15.2 million in 2021.
  • In the last 5 years, Abeona Therapeutics' EBT tumbled by 19485.09% in 2021 and then skyrocketed by 157897.65% in 2025.
  • Over the past 5 years, Abeona Therapeutics' EBT (Quarter) stood at -$46.7 million in 2021, then soared by 71.9% to -$13.1 million in 2022, then fell by 1.56% to -$13.3 million in 2023, then crashed by 33.31% to -$17.8 million in 2024, then dropped by 14.67% to -$20.4 million in 2025.
  • Its last three reported values are -$20.4 million in Q3 2025, $124.3 million for Q2 2025, and -$20.7 million during Q1 2025.